Influence of polyunsaturated fatty acids and their metabolites on stem cell biology

Nutrition

Volumn 27, Issue 1, 2011, Pages 21-25

  Das, Undurti N ^a,b  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b UND LIFE SCIENCES   (United States)

Author keywords

Alzheimer's disease; Cancer; Collagen vascular diseases; Coronary heart disease; Depression; Diabetes mellitus; Eicosanoids; Essential fatty acids; Hypertension; Lipoxins; Maresins; Nitrolipids; Proliferation; Protectins; Resolvins; Schizophrenia; Stem cells; Stroke

Indexed keywords

CD59 ANTIGEN; ESSENTIAL FATTY ACID; G PROTEIN COUPLED RECEPTOR; ICOSANOID; LIPOXIN; MARESIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITROLIPID; PHOSPHATIDYLINOSITOL 3 KINASE; POLYUNSATURATED FATTY ACID; PROTEIN KINASE B; RESOLVIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; COLLAGEN DISEASE; DEPRESSION; DIABETES MELLITUS; EMBRYONIC STEM CELL; ENZYME REGULATION; FATTY ACID METABOLISM; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASTIC DISEASE; NERVE CELL DIFFERENTIATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STEM CELL; STROKE; VASCULAR DISEASE;

FATTY ACIDS, ESSENTIAL; INFLAMMATION; STEM CELLS;

EID: 78649924532     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.04.003     Document Type: Review

References (77)

1. World Health Organization. Statistics. Available at: Accessed December, 2004. http://www.who.int/entity/healthinfo/statistics/bodgbddeathdalyestimates.xls.
2. Lopez A., Mathers C., Ezzati M., Jamison D., Murray C. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1714-1717.
3. Ezzati M., Vander Hoom S., Lawes C.M., Leach R., James W.P., Lopez A.D., et al. Rethinking the "Diseases of Affluence" paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med 2005, 2:e133.
4. Lim S.S., Gaziana T.A., Gakidou E., Reddy K.S., Farzadfar F., Lozana R., Rodgers A. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007, 370:2054-2625.
5. Das U.N. Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period. J Assoc Phys India 2006, 54:133-142.
6. Luc G., Bard J.-M., Juhan-Vague I., Ferrieres J., Evans A., Amouyel P., et al. C-reactive protein, interleukins-6, and fibrinogen as predictors of coronary heart disease. The PRIME study. Arterioscler Thromb Vasc Biol 2003, 23:1255-1261.
7. Das U.N. Is obesity an inflammatory condition?. Nutrition 2001, 17:953-966.
8. Das U.N. Aberrant expression of perilipins and 11-β-HSD-1 as molecular signatures of metabolic syndrome X in South East Asians. J Assoc Phys India 2006, 54:637-649.
9. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003, 107:391-397.
10. Das U.N. Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period?. J Nutr Biochem 2007, 18:701-713.
11. Das U.N. Is depression a low-grade systemic inflammatory condition?. Am J Clin Nutr 2007, 85:1665-1666.
12. Dougan M., Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med 2008, 205:267-270.
13. Lawrence T., Hagemann T., Balkwill F. Sex, cytokines, and cancer. Science 2007, 317:51-52.
14. Rao A.A., Sridhar G., Das U.N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007, 69:1272-1276.
15. Teixeira de Lemos E., Reis F., Baptista S., Pinto R., Sepodes B., Vala H., et al. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition 2009, 25:330-339.
16. Das U.N. Obesity: genes, brain, gut, and environment. Nutrition 2010, 26:459-473.
17. Das U.N. Metabolic syndrome pathophysiology: the role of essential fatty acids 2010, Wiley-Blackwell, Ames, Iowa.
18. Das U.N. Leucocyte activation in coronary heart disease: but how and why?. Eur Heart J 2008, 29:2317-2318.
19. Das U.N. Essential fatty acids-a review. Curr Pharm Biotechnol 2006, 7:467-482.
20. Das U.N. Essential fatty acids: biochemistry, physiology, and pathology. Biotechnology J 2006, 1:420-439.
21. Das U.N. Do polyunsaturated fatty acids behave as endogenous "polypill" ?. Med Hypotheses 2008, 70:430-434.
22. Das U.N. Can essential fatty acids reduce the burden of disease(s)?. Lipids Health Dis 2008, 7:9.
23. Das U.N. A perinatal strategy for preventing adult diseases: the role of long-chain polyunsaturated fatty acids 2002, Kluwer Academic Publishers, Boston.
24. Risé P., Pazzucconi F., Sirtori C.R., Galli C. Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis 2001, 11:88-94.
25. Risé P., Ghezzi S., Carissimi R., Mastromauro F., Petroni A., Galli C. Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol 2007, 571:97-105.
26. Das U.N. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008, 7:37.
27. Das U.N. Beneficial actions of polyunsaturated fatty acids in cardiovascular diseases: But, how and why?. Curr Nutr Food Sci 2008, 4:2-31.
28. Zuliani G., Galvani M., Leitersdorf E., Volpato S., Cavalieri M., Fellin R. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm Des 2009, 15:4087-4093.
29. Das UN. Lipoxins, resolvins, protectins, maresins and nitrolipids: connecting lipids, inflammation, and cardiovascular disease risk. Curr Cardiovasc Risk Rep (in press).
30. Chiang N., Serhan C.N. New mechanism for an old drug: aspirin triggers anti-inflammatory lipid mediators with gender implications. Compr Ther 2006, 32:150-157.
31. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000, 192:1197-1204.
32. Ohira T., Arita M., Omori K., Recchiuti A., Van Dyke T.E., Serhan C.N. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 2010, 285:3451-3461.
33. Das U.N. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot Essent Fatty Acids 1995, 52:387-391.
34. Rousseau-Ralliard D., Moreau D., Guilland J.C., Raederstorff D., Grynberg A. Docosahexaenoic acid, but not eicosapentaenoic acid, lowers ambulatory blood pressure and shortens interval QT in spontaneously hypertensive rats in vivo. Prostaglandins Leukot Essent Fatty Acids 2009, 80:269-277.
35. Serhan C.N., Yang R., Martinod K., Kasuga K., Pillai P.S., Porter T.F., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009, 206:15-23.
36. Ménesi D., Kitajka K., Molnar E., Kis Z., Belleger J., Narce M., et al. Gene and protein expression profiling of the fat-1 mouse brain. Prostaglandins Leukot Essent Fatty Acids 2009, 80:33-42.
37. Das U.N., Puskas L.G. Transgenic fat-1 mouse as a model to study the pathophysiology of various clinical conditions with particular reference to cardiovascular and neurological and psychiatric disorders. Lipids Health Dis 2009, 8:61.
38. Vijay Kumar K., Das U.N., Santhi Naidu K. Effect of cis-unsaturated fatty acids on cell membrane bound enzymes in vitro. Nutr Res 1992, 12:549-560.
39. Mozaffarian D., Ascherio A., Hu F.B., Stampfer M.J., Willett W.C., Siscovick D.S., Rimm E.B. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005, 111:157-164.
40. Wang L., Folsom A.R., Eckfeldt J.H. Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Nutr Metab Cardiovasc Dis 2003, 13:256-266.
41. Dyerberg J. Coronary heart disease in Greenland Inuit: a paradox. Implications for western diet patterns. Arctic Med Res 1989, 48:47-54.
42. Vijay Kumar K., Das U.N. Effect of cis-unsaturated fatty acids, prostaglandins and free radicals on angiotensin converting enzyme activity in vitro. Proc Soc Exp Biol Med 1997, 214:374-379.
43. Li C.C., Lii C.K., Liu K.L., Yang J.J., Chen H.W. N-6 and n-3 polyunsaturated fatty acids down-regulate cytochrome P-450 2B1 gene expression induced by Phenobarbital in primary rat hepatocytes. J Nutr Biochem 2006, 17:707-715.
44. Clarke S.D., Jump D. Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms. Prostaglandins Leukot Essent Fatty Acids 1997, 57:65-69.
45. Leroy J.L., Vanholder T., Mateusen B., Christophe A., Opsomer G., de Kruif A., et al. Non-esterified fatty acids in follicular fluid of dairy cows and their effect on developmental capacity of bovine oocytes in vitro. Reproduction 2005, 130:485-495.
46. Thangavelu G., Colazo M.G., Ambrose D.J., Oba M., Okine E.K., Dyek M.K. Diets enriched in unsaturated fatty acids enhance early embryonic development in lactating Holstein cows. Theriogenology 2007, 68:949-957.
47. 2+/PKC, PI3K/Akt, and MAPKs. Cell Physiol Biochem 2009, 23:53-64.
48. Feher I., Gidali J. Prostaglandin E2 as stimulator of haemopoietic stem cell proliferation. Nature 1974, 247:550-551.
49. Gidali J., Feher I. The effect of E type prostaglandins on the proliferation of haemopoietic stem cells in vivo. Cell Tissue Kinet 1977, 10:365-373.
50. Kurland J.I., Broxmeyer H.E., Pelus L.M., Moore M.A.S. Role of monocyte-macrophage-derived colony-stimulating factor and prostaglandin E in the positive and negative feedback control of myeloid stem cell proliferation. Blood 1978, 52:388-407.
51. Motomura S., Dexter T.M. The effect of prostaglandin E1 on hemopoiesis in long-term bone marrow cultures. Exp Hematol 1980, 8:298-303.
52. Pelus L.M., Gold E., Saletan S., Coleman M. Restoration of responsiveness of chronic myeloid leukemia granulocyte-macrophage colony-forming cells to growth regulation in vitro following preincubation with prostaglandin E. Blood 1983, 62:158-165.
53. Lindgren J.A., Stenke L., Mansour M., Edenius C., Lauren L., Nasman-Glaser B., et al. Formation and effects of leukotrienes and lipoxins in human bone marrow. J Lipid Mediat 1993, 6:313-320.
54. Tang L.Y., Kimmel D.B., Jee W.S., Yee J.A. Functional characterization of prostaglandin E2 inducible osteogenic colony forming units in cultures of cells isolated from the neonatal rat calvarium. J Cell Physiol 1996, 166:76-83.
55. Roux S., Pichaud F., Quinn J., Lalande A., Morieux C., Jullienne A., de Vernejoul M.C. Effects of prostaglandins on human hematopoietic osteoclast precursors. Endocrinology 1997, 138:1476-1482.
56. Cohn S.M., Schloemann S., Tessner T., Seibert K., Stenson W.F. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest 1997, 99:1367-1379.
57. Glasgow WC., Afshari C.A., Barrett J.C., Eling T.E. Modulation of the epidermal growth factor mitogenic response by metabolites of linoleic and arachidonic acid in Syrian hamster embryo fibroblasts. Differential effects in tumor suppressor gene (+) and (-) phenotypes. J Biol Chem 1992, 267:10771-10779.
58. Kawakita E., Hashimoto M., Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139:991-997.
59. Kim Y.H., Han H.J. High-glucose-induced prostaglandin E(2) and peroxisome proliferator-activated receptor delta promote mouse embryonic stem cell proliferation. Stem Cells 2008, 26:745-755.
60. Yun D.H., Song H.Y., Lee M.J., Kim M.R., Kim M.Y., Lee J.S., Kim J.H. Thromboxane A2 modulates proliferation and differentiation of adipose tissue-derived mesenchymal stem cells. Exp Mol Med 2009, 41:17-24.
61. Lee S.H., Na S.I., Heo J.S., Kim M.H., Kim Y.H., Lee M.Y., et al. Arachidonic acid release by H2O2-mediated proliferation of mouse embryonic stem cells: involvement of Ca2+/PKC and MAPKs-induced EGFR transactivation. J Cell Biochem 2009, 106:787-797.
62. Lee S.H., Kim M.H., Han H.J. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol Cell Physiol 2009, 297:C207-C216.
63. Hoggatt J., Singh P., Sampath J., Pelus L.M. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009, 113:5444-5455.
64. Yun S.P., Lee M.Y., Ryu J.M., Han H.J. Interaction between PGE2 and EGF receptor through MAPKs in mouse embryonic stem cell proliferation. Cell Mol Life Sci 2009, 66:1603-1616.
65. Goessling W., North T.E., Loewer S., Lord A.M., Lee S., Stoick-Cooper C.L., et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009, 136:1136-1147.
66. Lee J.H., Tachibana H., Morinaga Y., Fujimura Y., Yamada K. Modulation of proliferation and differentiation of C2C12 skeletal muscle cells by fatty acids. Life Sci 2009, 84:415-420.
67. Varney M.E., Hardman W.E., Sollars V.E. Omega 3 fatty acids reduce myeloid progenitor ell frequency in the bone marrow of mice and promote progenitor cell differentiation. Lipids Health Dis 2009, 8:9.
68. Wolfrum C., Shi S., Jayaprakash N., Jayaraman M., Wang G., Pandey R.K., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25:1149-1157.
69. Garcia-Gonzalo F., Belmonte J.C.I. Albumin-associated lipids regulate human embryonic stem cell self-renewal. PLoS One 2008, 3:e1384.
70. Ramesh G., Das U.N., Koratkar R., Padma M., Sagar P.S. Effect of essential fatty acids on tumor cells. Nutrition 1992, 8:343-347.
71. Belayev L., Marcheselli V.L., Khoutorova L., Rodriguez de Turco E.B., Busto R., Ginsberg M.D., Bazan N.G. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005, 36:118-123.
72. Hagberg C.E., Falkevall A., Wang X., Larsson E., Huusko J., Nilsson I., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010, 464:917-921.
73. Yang S.P., Morita I., Murota S. Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via Inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells. J Cell Physiol 1998, 176:342-349.
74. Stockmann C., Doedens A., Weidemann A., Zhangi N., Takeda N., Greenberg J.I., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-819.
75. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R.A., Martin J., Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997, 420:28-32.
76. Inoue H., Takamori M., Shimoyama Y., Ishibashi H., Yamamoto S., Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002, 136:287-295.
77. Zhang X., Morham S.G., Langenbach R., Baggs R.B., Young D.A. Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp Cell Res 2000, 254:232-240.